2020-004938-38: ADVANCE: A clinical study of Atezolizumab and Derazantinib for patients with advanced intrahepatic cholangiocarcinoma with gene FGFR2 fusions/rearrangements Die ADVANCE Studie: Eine einarmige, offene klinische Studie der Phase II zur Behandlung mit Atezolizumab und Derazantinib bei Patienten mit einem fortge-schrittenen intrahepatischen Cholangiokarzinom, das molekulare FGFR2 Alterationen (Gen-Fusionen/Rearrangements) aufweist |
|
|
| Not yet recruiting | 2 | 37 | Europe | Derazantinib, Derazantinib•2HCl / BAL087 / BAL0000087-001, Concentrate for solution for infusion, Capsule, hard, Tecentriq® 1.200 mg | Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, ROCHE Pharma AG, Basilea Pharmaceutica International Ltd. | Advanced non-resectable intrahepatic cholangiocarcinoma with positively confirmed FGFR2 fusion/rearrangements via NGS-Analysis, Advanced and inoperable intrahepatic bile duct cancer with positively confirmed FGFR2 genetic alterations, Diseases [C] - Cancer [C04] | | | | |
NCT05174650: Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements |
|
|
| Recruiting | 2 | 37 | Europe | Atezolizumab, Tecentriq, Derazantinib, ARQ 087 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Intrahepatic Cholangiocarcinoma | 12/25 | 08/26 | | |
2019-004505-27: A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03) |
|
|
| Not yet recruiting | 1/2 | 314 | Europe | Derazantinib, Paclitaxel EVER Pharma 6 mg/ml, Cyramza 100 mg/10ml, Tecentriq 1,200 mg, Cyramza 500 mg/50ml, [Ramucirumab], [Atezolizumab], [Paclitaxel], [Derazantinib], Capsule, hard, , Concentrate for solution for infusion, Paclitaxel EVER Pharma 6 mg/ml, Cyramza 100 mg/10ml, Tecentriq 1,200 mg, Cyramza 500 mg/50ml | Basilea Pharmaceutica International Ltd., Basilea Pharmaceutica International Ltd., Allschwil, Basilea Pharmaceutica International Ltd, Allschwil, Basilea Pharmaceutica International AG, Basilea Pharmaceutica International Ltd. | HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations, Stomach cancer, Diseases [C] - Cancer [C04] | | | | |
